Cortechs.ai announces official support of Nuance PowerScribe 360 in NeuroQuant®

Collaboration provides automatic generation of NeuroQuant volumetric data into radiology reports using PowerScribe® 360

(San Diego, CA) November 30, 2015 – Cortechs.ai, the leading medical software innovator providing solutions for quantitative brain volume analysis, is pleased to announce that NeuroQuant now supports Nuance PowerScribe ® 360, a technology collaboration will support accurate and automatic field population of PowerScribe 360 reports with NeuroQuant’s volumetric MRI data.

Hospitals, clinics, imaging and research centers worldwide will benefit from this expanded capability, which provides automatic and flexible data integration of NeuroQuant’s 3D T1 MRI brain structure measurements, with Nuance PowerScribe 360, the industry’s most trusted and widely used real-time radiology reporting solution.

“We are excited to work with Nuance to provide our customers with streamlined reporting of NeuroQuant data through PowerScribe 360,” said Guri Stark, Cortechs.ai’ CEO. “We believe this collaboration will significantly benefit many physicians and clinicians using NeuroQuant in increasing productivity and reducing transcription and data entry errors, allowing them to deliver better patient care.”

For more information about using PowerScribe with NeuroQuant, please visit Cortechs.ai at Booth 1861 (Hall A, South) during Radiological Society of North America’s (RSNA) 2015 Annual Meeting (Nov. 29 – Dec. 4, McCormick Place, Chicago).

About Cortechs.ai                                                                                                                                                         

Cortechs.ai develops and markets cutting-edge brain imaging solutions used by neurologists and radiologists in hundreds of clinics and research centers around the world. CorTechs’ flagship product, NeuroQuant®, is a breakthrough, 510(k) cleared software medical device that makes quantitative analysis of MRI images of the human brain a routine part of clinical practice.  As the first FDA cleared and CE marked medical device capable of automatically detecting and quantifying atrophy in the human brain, NeuroQuant brings sophisticated, accurate, and fully automated MRI post-processing capabilities to the physician’s desktop or mobile device. This provides neurologists, radiologists, and clinical researchers with a convenient and cost-effective means to quantify atrophy of brain structures to help diagnose a variety of brain disorders, including conditions such as Alzheimer’s disease, epilepsy, multiple sclerosis and traumatic brain injury. Please visit cortechs.ai for further information.

More Resources

03/09/2025

Advancing TBI Evaluation with AI-Driven MRI Analysis: A New Era in Brain Health

AI-driven MRI with NeuroQuant® enhances TBI assessment, tracks recovery, and supports better treatment decisions.

03/06/2025

Case Study: Leveraging NeuroQuant® for Accurate Diagnosis of Traumatic Brain Injury

This case highlights the power of advanced neuroimaging tools in delivering precise, evidence-based diagnostics to enhance patient care and clinical decisions.

02/26/2025

Traumatic Brain Injury in Athletes: The Role of the NeuroQuant and Automated Volumetric Tracking

NeuroQuant enables objective brain volume tracking for early TBI detection, recovery monitoring, and safer return-to-play decisions.

02/25/2025

OnQ™ Prostate Solution Enhances Collaboration and Improves MRI for Cancer Detection with RSI Technology

OnQ Prostate enhances MRI tissue characterization, improving sensitivity and specificity in cancer detection, & bridges gaps between radiologists and urologists

02/15/2025

NeuroQuant® Dementia: Advancing Alzheimer’s Disease Care in the Era of DMTs

AI-driven brain volumetric analysis is revolutionizing Alzheimer’s care, providing precise diagnostic support, monitoring, and early detection.

02/09/2025

NeuroQuant® MS:  Advancing Precision in Multiple Sclerosis

Dr. Suzie Bash discusses NeuroQuant MS, noting its ability to segment plaques, analyze volume, and track lesion burden for assessing disease progression
Scroll to Top